NIKKEI 225
30,526.88 -711.06 (-2.28%) HANG SENG
17,195.84 -135.38 (-0.78%) CRUDE OIL
84.55 -4.68 (-5.24%) GOLD FUTURES
1,832.60 -8.90 (-0.48%) DOW
33,058.82 +56.44 (+0.17%) Bitcoin GBP
22,885.47 +332.57 (+1.47%)
Valneva SE (VALN)
| Previous close | 10.85 |
| Open | 10.91 |
| Bid | 10.95 x 1200 |
| Ask | 11.11 x 1100 |
| Day's range | 10.84 - 11.05 |
| 52-week range | 9.07 - 17.05 |
| Volume | |
| Avg. volume | 4,695 |
| Market cap | 797.25M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | 60.83 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Delive
- Globe Newswire
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued recovery of the travel industry as well as from price increasesBringing total revenues to €73.7 million in the first half of 2023 Strong cash position of €204.4 million as at June 30, 2023 Excludes up to an additional $100 million made available as part of a recent upsized financing arrangemen
- Globe Newswire
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15 well-tolerated in all age groups following booster dose Saint-Herblain (France) & New York, September 7, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine ca
